Skip to main content
PMC home page
Gut logoLink to Gut
. 1978 Apr;19(4):249–252. doi: 10.1136/gut.19.4.249

Significance of anergy to dinitrochlorobenzene (DNCB) in inflammatory bowel disease: family and postoperative studies.

S Meyers, D B Sachar, R N Taub, H D Janowitz
PMCID: PMC1411921  PMID: 648933

Abstract

To evaluate the pathogenetic significance of impaired cellular immunity in inflammatory bowel disease (IBD), we have measured the cutaneous responsiveness to dinitrochlorobenzene (DNCB) among 58 patients with IBD, 33 with Crohn's disease and 25 with ulcerative colitis, 63 of their clinically normal relatives, 24 additional ileitis and colitis patients who had undergone resection of all visibly diseased bowel, and 23 control subjects. Cutaneous anergy to DNCB was demonstrated among 70% of the patients with CD and 48% of those with UC, as against only 9% of the controls (p less than 0.001). There was no increased incidence of anergy among either 44 first-degree relatives (7%) or 19 spouses (3%), nor was there any special proclivity toward anergy among six pairs of patients with familial inflammatory bowel disease. In Crohn's disease, anergy was still present after bowel resection in six of 10 patients (60%), while in ulcerative colitis anergy was found after colectomy in only two of 14 patients (14%). Our data suggest that the immune defect in patients with inflammatory bowel disease may be a secondary phenomenon. In ulcerative colitis, the defect appears to reverse after colectomy, but in Crohn's disease it persists despite resection. This finding is consistent with the observed tendency of Crohn's disease, but not ulcerative colitis, to inexorable postoperative recurrence.

Full text

PDF
249

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binder H. J., Spiro H. M., Thayer W. R., Jr Delayed hypersensitivity in regional enteritis and ulcerative colitis. Am J Dig Dis. 1966 Jul;11(7):572–574. doi: 10.1007/BF02233570. [DOI] [PubMed] [Google Scholar]
  2. Bolton P. M., James S. L., Newcombe R. G., Whitehead R. H., Hughes L. E. The immune competence of patients with inflammatory bowel disease. Gut. 1974 Mar;15(3):213–219. doi: 10.1136/gut.15.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Catalona W. J., Taylor P. T., Rabson A. S., Chretien P. B. A method for dinitrochlorobenzene contact sensitization. A clinicopathological study. N Engl J Med. 1972 Feb 24;286(8):399–402. doi: 10.1056/NEJM197202242860804. [DOI] [PubMed] [Google Scholar]
  4. Dunne W. T., Cooke W. T., Allan R. N. Enzymatic and morphometric evidence for Crohn's disease as a diffuse lesion of the gastrointestinal tract. Gut. 1977 Apr;18(4):290–294. doi: 10.1136/gut.18.4.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Goodman M. J., Skinner J. M., Truelove S. C. Abnormalities in the apparently normal bowel mucosa in Crohn's disease. Lancet. 1976 Feb 7;1(7954):275–278. doi: 10.1016/s0140-6736(76)91404-5. [DOI] [PubMed] [Google Scholar]
  6. Greenstein A. J., Sachar D. B., Pasternack B. S., Janowitz H. D. Reoperation and recurrence in Crohn's colitis and ileocolitis Crude and cumulative rates. N Engl J Med. 1975 Oct 2;293(14):685–690. doi: 10.1056/NEJM197510022931403. [DOI] [PubMed] [Google Scholar]
  7. Jones J. V., Housley J., Ashurst P. M., Hawkins C. F. Development of delayed hypersensitivity to dinitrochlorobenzene in patients with Crohn's disease. Gut. 1969 Jan;10(1):52–56. doi: 10.1136/gut.10.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Korsmeyer S. J., Williams R. C., Jr, Wilson I. D., Strickland R. G. Lymphocytotoxic antibody in inflammatory bowel disease. A family study. N Engl J Med. 1975 Nov 27;293(22):1117–1120. doi: 10.1056/NEJM197511272932203. [DOI] [PubMed] [Google Scholar]
  9. Lewkonia R. M., McConnell R. B. Progress report. Familial inflammatory bowel disease--heredity or environment? Gut. 1976 Mar;17(3):235–243. doi: 10.1136/gut.17.3.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Meuwissen S. G., Schellekens P. T., Huismans L., Tytgat G. N. Impaired anamnestic cellular immune response in patients with Crohn's disease. Gut. 1975 Nov;16(11):854–860. doi: 10.1136/gut.16.11.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Meyers S., Sacher D. B., Taub R. N., Janowitz H. D. Anergy to dinitrochlorobenzene and depression of T-lymphocytes in Crohn's disease and ulcerative colitis. Gut. 1976 Nov;17(11):911–915. doi: 10.1136/gut.17.11.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sachar D. B., Meyers S., Janowitz H. D. Anergy in Crohn's disease. Br Med J. 1977 Mar 12;1(6062):712–713. doi: 10.1136/bmj.1.6062.712-d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sachar D. B., Taub R. N., Brown S. M., Present D. H., Korelitz B. I., Janowitz H. D. Imparied lymphocyte responsiveness in inflammatory bowel disease. Gastroenterology. 1973 Feb;64(2):203–209. [PubMed] [Google Scholar]
  14. Sachar D. B., Taub R. N., Ramachandar K., Meyers S., Forman S. P., Douglas S. D., Janowitz H. D. T and B lymphocytes and cutaneous anergy in inflammatory bowel disease. Ann N Y Acad Sci. 1976;278:565–573. doi: 10.1111/j.1749-6632.1976.tb47071.x. [DOI] [PubMed] [Google Scholar]
  15. Segal A. W., Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet. 1976 Jul 31;2(7979):219–221. doi: 10.1016/s0140-6736(76)91024-2. [DOI] [PubMed] [Google Scholar]
  16. Strickland R. G., Korsmeyer S., Soltis R. D., Wilson I. D., Williams R. C., Jr Peripheral blood T and B cells in chronic inflammatory bowel disease. Gastroenterology. 1974 Oct;67(4):569–577. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES